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Abstract 
 
Myocardial infarction occurs when oxygen is depleted from cardiac muscle.  Post 
myocardial infarction, the left ventricular wall is weakened due to the formation of scar tissue. 
As a result, a ventricular aneurysm may occur. There are numerous current treatment methods 
for ventricular aneurysms; however, none of them have been proven to promote cardiac 
regeneration. This project aims to find a method of reinforcing the weakened tissue and restoring 
normal cardiovascular function. A scaffold for cardiac regeneration will provide the long term 
reinforcement necessary to prevent ventricular aneurysms and restore normal heart function. 
Human mesenchymal stem cells (hMSCs) are commonly used because of their ability to 
differentiate into other cell types, including cardiac myocytes. This paper proposes a method of 
restoring cardiac tissue through the use of a novel implantation method using an hMSC seeded 
scaffold that will temporarily support the area of weakened tissue and aid in the production of 
cardiac myocytes to re-establish a healthy ventricular wall. 
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Executive Summary 
 
 Cardiovascular disease is the leading cause of death for both men and women in the 
United States .
1
 The most common cause of cardiovascular disease is the narrowing or blockage 
of the coronary artery, which typically leads to a heart attack.
2
 Annually in the United States, 1.2 
million people suffer from heart attacks. Of those 1.2 million people, over 40% of them are 
suffering from a recurring heart attack.
3
 After a heart attack, which is also known as myocardial 
infarction, the left ventricular wall is weakened due to the formation of scar tissue. This scar 
tissue has inferior mechanical properties when compared to normal myocardial tissue. As a 
result, a ventricular aneurysm may occur.  
The two current surgical treatment methods for ventricular aneurysms are: direct linear 
closure and endoventricular patch plasty. Direct linear closure involves an excision of the scar 
tissue followed by reconstruction of the left ventricular wall in order to close the wound; 
endoventricular patch plasty involves excision of the scar tissue followed by replacement with a 
biomaterial patch.
4
 Unfortunately, neither of these treatment methods replace healthy 
myocardium mechanically and biologically. This project aims to find a method of reinforcing the 
weakened tissue and restoring normal cardiovascular function. A scaffold for cardiac 
regeneration will provide the long term reinforcement necessary to prevent ventricular 
aneurysms and restore normal heart function. Human mesenchymal stem cells (hMSCs) are 
commonly used because of their ability to differentiate into other cell types, including cardiac 
myocytes. This paper proposes a method of restoring cardiac tissue through the use of a novel 
implantation method using an hMSC seeded scaffold that will temporarily support the area of 
weakened tissue and aid in the production of cardiac myocytes to re-establish a healthy 
ventricular wall. 
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Chapter 1: Introduction 
 
Cardiovascular disease is the leading cause of death for both men and women in the 
United States .
1
 Every 34 seconds a person in the U.S. dies from cardiovascular disease, resulting 
in more than 2500 deaths each day.
4, 5
 The most common cause of cardiovascular disease is the 
narrowing or blockage of the coronary artery, which typically leads to a heart attack.
2
 Annually 
in the United States, 1.2 million people suffer from heart attacks. Of those 1.2 million people, 
over 40% of them are suffering from a recurring heart attack.
3
  A heart attack occurs when the 
blood supply to the heart is blocked. This depletes the heart muscle of oxygen, and after only a 
few minutes, the tissue may be irreparably damaged. This is known as a myocardial infarction. 
Scar tissue typically forms over the damaged tissue; however, it does not regain full function. As 
a result, the cardiac output of the heart is significantly reduced and the strength of the tissue is 
diminished.  
Thinning of the myocardial tissue may result in a ballooning effect which is known as a 
ventricular aneurysm. Depending on their size, aneurysms can be asymptomatic or fatal. The 
rupturing of a ventricular aneurysm causes an opening to form in the ventricular wall. This 
diminishes the ability of the ventricle to withstand pressure, rendering it inoperative. The 
probability of an aneurysm rupturing is a function of its size. Ventricular aneurysms also give 
rise to further complications such as blood clotting and arrhythmias.
6
 Blood clots become more 
prevalent in patients with a ventricular aneurysm due to the decreased contractility of the 
ventricular wall. As a result, pooling of the blood may occur, which causes turbulent blood flow. 
Turbulent blood flow results in damage to the cells. The damaged cells initiate a clotting 
cascade. Ultimately, a fibrin mesh coagulates the cells and depending on the size, it may block 
the passage of blood through a vessel.
2
 If blockage occurs in the coronary arteries, myocardial 
infarction may result.   
Arrhythmias are abnormal heart rhythms caused by a disruption in the electrical system 
of the cardiac muscle.
2
 If tissue damage occurs in an area responsible for propagating electrical 
pulse, it will cause a disruption that could affect the rhythm of the heart. Depending on the 
severity of the arrhythmia, a pacemaker may be necessary to control electrical impulses 
throughout the heart.  
5 
 
Blood clotting and arrhythmias, commonly caused by ventricular aneurysms, have many 
adverse effects on the heart. Due to the adverse affects that may arise from this disorder, it is 
necessary to find a method of reinforcing the weakened tissue and restoring normal 
cardiovascular function. A scaffold for cardiac regeneration will provide the long term 
reinforcement necessary to prevent ventricular aneurysms and restore normal heart function. This 
paper proposes a method of restoring cardiac tissue through the use of a human mesenchymal 
stem cell (hMSC) seeded scaffold that will temporarily support the area of weakened tissue and 
aid in the production of cardiac myocytes to re-establish a healthy ventricular wall.
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Chapter 2: Background 
2.1 Healthy Human Heart 
 
The human heart is essentially the “central powerhouse” of the circulatory system. The 
heart is responsible for circulating blood throughout the body. The blood not only supplies 
oxygen and nutrients to the body’s tissues and organs, but it also removes and transports waste to 
the kidneys, the liver, and the lungs. The heart contracts and relaxes in a beating rhythm about 
100,000 times per day in order to circulate blood.
7
 The anatomy of the heart and the flow of 
blood through it are shown below in figure 1. 
 
Figure 1: Cross Section of Human Heart
7
 
 
Deoxygenated blood flows into the right atrium of the heart via the vena cava. It then passes 
through a tricuspid valve, which is a valve with three flaps, into the right ventricle. The right 
ventricle pumps the blood into the pulmonary artery, where it is taken to the lungs to become 
oxygenated.  The oxygenated blood is taken away from the lungs and brought back to the left 
atrium of the heart via the pulmonary vein. The oxygenated blood passes through a bicuspid 
valve, which has two flaps, into the left ventricle where it is pumped into the aorta and taken 
throughout the body.
2
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The coronary arteries are the vessels that supply blood to the heart. Oxygenated blood 
leaves the left ventricle and passes through the aorta. The ascending aorta splits into two passage 
ways, one of which delivers the oxygenated blood to the left and right coronary arteries; the 
other leading to the aortic arch. The left coronary artery supplies blood to the left atrium and 
ventricle, while the right coronary artery supplies blood to the right atrium and ventricle. The 
coronary arteries run along the epicardium of the heart, supplying blood to the myocardium. 
Their role is vital in the nourishment of the myocardial tissue, since it is too thick to fully obtain 
nourishment from the blood passing through the chambers of the heart.
2
   
The wall of the heart is composed of three layers: the epicardium, the myocardium, and 
the endocardium. The epicardium and the endocardium contain type I and type III collagen and 
elastin; in addition, the endocardium contains endothelial cells.
8, 9
 The myocardium consists of 
cardiac muscle fibers, including fibroblasts and myocytes in a collagen matrix. These muscle 
fibers facilitate contraction of the heart via conduction of electric signals.
8, 10
 The coronary 
arteries supply blood to the epicardium, the outermost layer, where it penetrates to the 
myocardium.
11
 Therefore, when disruption of this blood flow occurs, damage or death to that 
particular region of the heart may occur.  
2.2 Rodent Heart 
 
The systemic and pulmonary circulation of a rodent heart is identical to that of a healthy 
human heart. As seen in Figure 2 below, the blood enters the heart at the right atrium via the 
vena cava.
12
 It passes through a valve into the right ventricle then into the pulmonary artery. The 
pulmonary artery takes the deoxygenated blood to the lungs. From the lungs, the now 
oxygenated blood is taken to the left atrium via the pulmonary vein. From the left atrium, it 
enters the left ventricle, where it is pumped into the aorta and taken throughout the body.  
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Figure 2: Blood Flow Through Rodent Heart
12
  
 
The differences between the human heart and the rodent heart lie in the size, “the 
distribution coronary artery blood flow, dual blood supply in the rat to the right and left atrium of 
the heart, and heart to body weight ratios.”12 The average rodent heart beats at a rate of about 400 
beats per minute, whereas a healthy human heart functions at about 70 beats per minute.
13
 
Despite these differences, the rodent heart serves as a favorable preliminary step in modeling the 
function of a scaffold for cardiac regeneration in the heart. 
 
2.3 Myocardial Infarction 
 
Coronary artery disease is one of several causes of a disruption of blood flow through the 
coronary arteries. A disruption in the blood flow may cause insufficient blood supply to the 
myocardium; this is also known as ischemia.
7
 Ischemia occurs in three common ways: 
atherosclerosis, embolism, or artery spasm.
8, 14
 Atherosclerosis is the congestion of the coronary 
artery as a result of plaque build-up on the vessel wall. Blockage of the coronary artery from the 
plaque may cause myocardial infarction. An arterial embolism is the blockage of an artery due to 
a blood clot.
15
 When a blood clot blocks the coronary artery, it hinders blood flow to the heart, 
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preventing oxygen from reaching the myocardial tissue. An arterial spasm is a spasm of the 
arterial wall due to plaque build-up.
15
 When this occurs in the coronary artery, the blood flow 
diminishes leading to a lack of oxygen supply to the tissue. In all the aforementioned cases, if the 
blood supply to the myocardium is blocked for more than a few minutes, it may cause damage or 
death to a portion of the tissue, also known as myocardial infarction. 
Myocardial infarction, also known as a heart attack, occurs when blood supply to the 
myocardium is reduced or blocked due to congestion of one or more coronary arteries. 
Diminished blood flow, as a result of the blockage, reduces oxygen supply to the cardiac cells. 
Oxygen depletion greatly diminishes ATP production in the cells. A lack of ATP production 
results in reduced muscle contractility. If this persists for several minutes, tissue death occurs. In 
the weeks and month following tissue death, remodeling of the tissue occurs, resulting in scar 
tissue formation. The scar tissue primarily consists of fibroblasts and aligned fibrous collagen, 
which have inferior contractility to the native myocardium. These inferior properties are 
responsible for the formation of ventricular aneurysms.
16
 
 
2.4 Post-Myocardial Infarction  
 Infarcted myocardium eventually develops into scar tissue. The scar tissue, which is 
mechanically unproductive, does not conduct the electrical charges that a healthy myocardium 
does. In fact, the scar tissue interrupts the normal charge pathways; therefore, the disrupted 
electrical pathways may result in arrhythmias, an abnormal beating of the heart. In addition, the 
heart does not produce the same output per contraction as it did prior to the occlusion. This also 
occurs due to a thinning of the ventricular wall at the site of the scar tissue. The increased 
pressure and thinning of the ventricular wall cause the heart to stray from its normal elliptical 
shape to a spherical shape, also known as a ballooning effect called ventricular aneurysms. 
Myocytes in the region try to compensate for the thinning and the reduced cardiac output by 
undergoing hypertrophy to increase healthy muscle mass.
17
 As the heart muscle in the scarred 
region tries to compensate for its deficiencies, the stress on the heart increases. The extra muscle 
tissue produced by the myocytes amplifies the stress on the heart with each contraction. As a 
result, many complications may arise. 
To treat, doctors use biomaterial scaffolds to provide extra support. These scaffolds 
provide mechanical support to the wall of the heart, which not only aid in maintaining the 
10 
 
elliptical shape, but also support the higher stresses exerted on the heart.
18
 In patients with large 
scarring and left ventricular dysfunction, scaffolds have been shown to improve the overall heart 
function.
19
 
Another side effect of infarction is congestive heart failure (CHF). If infarction 
significantly reduces cardiac output so much that systemic blood supply is insufficient, fluid 
build up, or edema, occurs. This condition is not acutely life threatening however, it causes 
shortness of breath which can limit physical activity.
6
 
 
2.5 Current Treatment Methods 
 
The two current treatment methods for ventricular aneurysms are: direct linear closure 
and endoventricular patch plasty. The direct linear closure procedure involves an excision of the 
scar tissue followed by reconstruction of the healthy tissue in order to close the wound. The 
advantage with this procedure is that there is a low probability of an inflammatory or an immune 
response occurring, since no biomaterials are used. The disadvantages associated with the direct 
linear closure procedure are: increased tension in the ventricular wall and the potential for a lack 
of tissue to facilitate wound closure.
20
 The endoventricular patch plasty involves excision of the 
scar tissue followed by replacement with a biomaterial patch. The current gold standard material 
of choice is Dacron.
21
 The advantages with this procedure are: potential reduction of ventricular 
wall tension, and revascularization and alignment of the muscle fibers.
20
 The disadvantages with 
an endoventricular patch plasty are: the potential for an inflammatory or an immune response, 
and no cardiac regeneration. 
2.6 Cardiac Regeneration  
 
Cardiac patches are being researched as an important method of cardiac regeneration. 
Cardiac patches, or biomaterial scaffolds, are seeded with myocardial cells and implanted into 
the heart. The implanted scaffolds are being researched for their ability to stimulate regeneration 
of fully-functional myocardial cells that aid in the function of the heart.  
Cardiac regeneration is a heavily debated topic among researchers. It was previously 
believed that myocardial cells terminally differentiate and do not divide in the adult heart. It was 
11 
 
also believed that the heart can only grow through myocyte hypertrophy.
22
 However, recent 
studies have challenged this point of view, citing extra-cardiac cardiomyocytes growing in the 
hearts of several patients after cardiac transplants as evidence.
23
   
The alternate point of view among researchers is that some myocardial cells divide. There 
is evidence that suggests that myocytes immediately express early and late growth-related genes 
after infarction.
24
 These genes increase the number of dividing myocytes by a factor of 3 to 4, 
one week after infarction. The effects of this increase can be easily neglected since cell 
proliferation cannot occur where there is insufficient blood supply (i.e. the infarction site).
25
 
Since the infarction site is not ideal for cell proliferation, researchers have developed scaffolds 
that can be used to aid cardiac regeneration.  
2.6.1 Scaffolds  
Scaffolds are commonly used as a foundation of cardiac regeneration. Scaffolds  
are vital for sustained myocardial cell growth and general cardiac regeneration because they 
provide mechanical support for the cells until they form an extracellular matrix.
26
 There are 
several varieties of scaffolds available, each with their strengths and weaknesses. 
Park et al. developed a list of requirements that an ideal scaffold must meet: 
(1) Highly porous with large interconnected pores (to facilitate mass transport), (2) 
hydrophilic (to enhance cell attachment), (3) structurally stable (to withstand the shearing 
forces during bioreactor cultivation), (4) degradable (to provide ultimate biocompatibility 
of the tissue graft), and (5) elastic (to enable transmission of contractile forces).
27
 
 
Dacron, a polyester mesh, is currently the gold-standard of treatment for endoventricular 
patch plasties. It has been used for its durability and flexibility.
28
 However, Dacron has 
mechanical properties much higher than that of native myocardium, resulting in a material 
mismatch. In addition, it has been shown to induce thrombus formation.
29
 While Dacron is a 
suitable material for a patch, it is not ideal for regeneration. Dacron does not resorb and it does 
not provide an ideal environment for cell survival and proliferation. In addition, it has been 
shown that Dacron is antigenic and induces an inflammatory response.
30
 This creates an 
environment that is not conducive to cell survival and proliferation. 
While Dacron patches are currently the gold-standard, Veritas is becoming a popular 
material choice for a scaffold to induce regeneration. Veritas is uncross-linked bovine 
pericardium. Veritas has been shown to resorb and promote tissue ingrowth and angiogenesis.
31
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Since vascularization is necessary for the survival of cells, this provides an ideal environment for 
cell viability and proliferation. Finally, the material has been shown to be biocompatible.
31
 The 
pitfall of this material is that it is derived from bovine pericardium. While this material is 
advertised as mostly acellular, there is a potential for DNA extraction, which could elicit an 
immune response.  
Porcine urinary bladder matrix (UBM) is currently being researched as a replacement for 
the non-degradable patches that are commonly used in clinical environments. The experiment 
which Robinson et al. conducted demonstrated that the replacement tissue consisted of 
characteristics of healing scarred and normal myocardium. Robinson et al.’s experiment also 
showed that only 10% of the UBM was remaining three months after implant 
32
.  Having 
degradation properties is advantageous for implantable scaffolds because they do not require a 
second surgery. However, if the degradation rate does not match the rate of regeneration 
problems may arise.  
 Fibrin glue is a common surgical sealant and adhesive that is composed of fibrinogen and 
thrombin.
33
 Christman et al. concluded that transplanted cells are more likely to survive when 
injected in fibrin glue. However, fibrin glue does not have a positive effect on cell retention.
34
   
2.6.2 Stem Cells  
Stem cells are cells that have the ability to develop into various different cell types in the 
body. Currently, bone marrow is the most common source of cells for cardiac repair. The reasons 
for the use of bone marrow include: its ability to renew itself long-term and its ability to 
recompose a comprehensive array of progenitor cells after single-cell grafting.
35
 Orlic et al. was 
able to promote myocardial regeneration in mice by injecting bone marrow cells into the 
infarction zone.
36
 Potapova et al. was able to increase stroke work in canine hearts with defects 
by implanting bone marrow-derived stem cells.
37
   
Human mesenchymal stem cells (hMSCs), which are derived from the bone marrow, are 
noted as having the ability to differentiate into cardiac myocytes, among other cell lines such as 
chondrocytes, osteocytes, and adipose cells.
38
 Studies have shown that implantation of hMSCs in 
the scar tissue of the heart has improved heart function.
38
 However, it is unknown whether this is 
due to cardiac myocyte proliferation or hMSC differentiation. 
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2.6.3 Stem Cell Seeded Scaffolds 
 Scaffolds are commonly used as a foundation of cardiac regeneration. Scaffolds are vital 
for sustained myocardial cell growth and general cardiac regeneration because they provide 
mechanical support for the cells until they form an extracellular matrix.
26
 Park et al. developed a 
list of requirements that an ideal scaffold must meet. Some of these requirements include high 
porosity with interconnected pores to facilitate cell attachment and mass transport, a hydrophilic 
material to aid in cell attachment, and degradation properties for biocompatibility purposes.
27
 
 A scaffold that meets such requirements also needs to be seeded with stem cells to aid in 
some form of tissue regeneration. While cell density can be arbitrary, Table 1 summarizes some 
stem cell seeded scaffolds and the cell densities chosen by each group. This information will be 
valuable for determining the cell density that will be used for this design.  
Type of cell Cell Count Scaffold Reference 
Myoblasts 80 x 10
6
 cells/cm
2 
Homologous acellular matrix 
39
 
Bone marrow-derived 
mononuclear cells 
8 x 10
6 
cells/cm
2 
PGCL polymer 
40
 
Bone marrow MSCs 1 × 10
5
 cells/cm
2
 Bovine pericardium 
41
 
Cardiomyocytes  6.67 × 10
5
 cells/cm
2 
3D collagen-based matrix 
42
 
Table 1: Cellular Scaffold Seedings in Rodent Models 
 
2.6.4 Growth Factors 
Growth factors are another method of myocardial regeneration that has had some success. 
Vascular endothelial growth factor (VEGF) is commonly used in coalition with stem cells to 
promote cardiac regeneration. In order for cells to survive in the scar tissue, vascularization must 
occur. VEGF has been shown to stimulate endothelial cell proliferation, which results in 
angiogenesis. Angiogenesis is vital for the regeneration of myocardial tissue.
43
 The use of 
growth factors appears to be a promising route as a method of promoting cardiac regeneration. 
Matrix-metallo proteinases (MMPs) are enzymes that are involved in ventricular 
modeling through degradation of scar tissue.
44
 Studies show that MMPs have an elevated 
concentration in the plasma of patients with congenital heart failure or ischemic tissue.
44
 Finally, 
another study has shown that the ventricular dysfunction is lengthened when MMPs are 
inhibited.
44
 This illustrates the importance of MMPs in the remodeling process, and as a result, 
consideration of MMP usage in scaffolds for cardiac regeneration is pertinent. 
14 
 
Chapter 3: Project Approach 
 
3.1 Project Hypothesis 
 
Unlike the current, conventional treatments of myocardial infarction, this project aims to 
develop a clinically applicable cardiac scaffold that actively seeks to regenerate cardiac tissue in 
vivo. It is hypothesized that the final scaffold design will regenerate cardiac tissue and restore 
myocardial function. The scaffold must be clinically viable, must have similar mechanical 
properties to the existing patches, must have regenerative properties, and must be successfully 
implanted into rats to meet this hypothesis.  
3.2 Project Assumptions 
 
 There are assumptions that the group has made in order to allow this project to be 
completed within the time limits that are present. The problems of heart disease and myocardial 
infarction have been simplified in order to meet the required goals of this project in a timely 
manner. Some of the assumptions made by this project may not be accepted by every 
stakeholder; however, verifying these assumptions is well beyond the scope of this project. The 
following assumptions have been made: 
• Following myocardial infarction, regeneration of the myocardium will improve cardiac 
function.  
• Stem cells, specifically human mesenchymal stem cells, migrate to the infarction region 
and play an important role in myocardial regeneration.  
• A fatigue testing apparatus can simulate the wear that a composite scaffold undergoes in 
vivo. 
• Cell growth in vitro can model myocardial regeneration.  
• Rats are an acceptable model for the human anatomy.  
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3.3 Project Goals 
 
 The purpose of this project was to develop and implant a scaffold that will regenerate 
cardiac tissue in the infarcted heart. The precise goals of this project are to: 
• Develop a prototype scaffold that is cost effective, easily implantable, biocompatible, 
clinically applicable, and maintenance-less.   
• Select suitable materials with the necessary mechanical and regenerative properties to 
support a section of the ventricular myocardium.  
• Determine the mechanical properties of the candidate materials by testing them 
independently and in different combinations, with various procedures. 
• Design a fatigue apparatus in order to test the fatigue properties of the candidate 
materials. 
• Characterize the ability of the candidate materials to promote the viability and migration 
of human mesenchymal stem cells.  
• Implant the selected scaffold in rodents in order to evaluate the effectiveness of the 
scaffold.  
16 
 
Chapter 4: Design 
Professor Gaudette gave the group the following initial client statement for the project: 
 
“Design a scaffold to promote cardiac regeneration for use in the surgical 
treatment of ventricular aneurysms. “ 
 
Using this client statement, objectives, functions, constraints, and specifications were 
formed. Before such details could be defined, the stakeholders needed to be considered. Once the 
stakeholders and their needs were outlined, the group was able to follow the engineering design 
process to narrow the scope of the project. The objectives defined the final goals for the scaffold. 
The functions outlined the means the means that would be used in order to achieve the goals. The 
constraints limited the design space and the potential design options. Finally, the specifications 
set specific requirements for the design. 
 
4.1 Stakeholders 
Defining the stakeholders of the project was a crucial step in the design process. It 
allowed the group to determine who the scaffold was being designed for in order to deliver the 
most appropriate product. The main stakeholder is Professor Glenn Gaudette, who is an assistant 
professor of Biomedical Engineering at Worcester Polytechnic Institute. Professor Gaudette is an 
expert in the field of cardiac tissue engineering and his work is funded by the American Heart 
Association.  
Another set of key stakeholders in this project are Dan Filipe and Megan Murphy. Both 
Dan and Megan are Biomedical Engineering graduate students at Worcester Polytechnic 
Institute. This project is largely based off of their study “Design of a Composite Scaffold for 
Myocardial Regeneration Following Infarction” which was completed in 2007.  
The needs of Professor Gaudette are: to deliver a finished product by the final deadline of 
April 2008 and to fulfill the initial client statement. Also, Professor Gaudette is expecting a 
useful product with clinical applicability. Dan and Megan’s needs are to continue their research, 
which is primarily based on the study that they began last year. Their research was primarily 
theoretical, while this project aims to take the results of their research and apply it practically. 
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Beyond the team of Professor Gaudette, Dan, and Megan, who are assisting the team on 
this project, two additional stakeholders are: the patients for whom the scaffold is being designed 
for and the cardiac surgeons who will be implanting them. It is imperative to consider the needs 
of these two parties. The patient’s needs are: safety and usefulness (ideally the scaffold is 
implanted and regenerates lost cardiac myocytes without causing any adverse effects or harm). 
The cardiac surgeons need a product that is easy to implant as well as one that does not require 
pre-surgical preparation. In order to ensure that these needs are met, the team interviewed Adam 
Saltman M.D., Ph.D., the Director of Cardiothoracic Surgical Research at 
Maimonides Medical Center in Brooklyn, NY. Dr. Saltman has had experience with implanting 
both Urinary Bladder Matrix and Veritas in canine models. He indicated that Veritas was easy to 
work with and had the ability to self seal. In other words, once the Veritas was sutured into the 
heart, the material would seal around the sutures, which prevented blood leakage through the 
patch. This information was pertinent in the future consideration of Veritas as a scaffold 
candidate.  
 After considering the needs of all the stakeholders, the group considered their needs. 
This group needed to stay within the range of the time span and budget, while at the same time 
delivering a product that satisfied the needs of all the stakeholders. Once the group outlined all 
the needs of the stakeholders, the next step in the design process was to define the objectives, 
constraints, functions, and specifications. Those assisted in creating design alternatives as well as 
choosing a final design. 
4.2 Objectives, Functions, Constraints 
 Defining a set of design objectives is a crucial part of the design process. It gives the 
designers a chance to think about what they want their design to do.  Following much thought 
and brainstorming, the group formulated the following objectives for the composite scaffold. 
      Composite scaffold for cardiac cell regeneration 
o The scaffold should be safe 
 Biocompatible material 
 Sterile 
o The scaffold should be useful 
 The scaffold should regenerate cardiac cells 
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 Promote cell viability  
 The scaffold should provide mechanical stability 
 Reliable mechanical properties 
 Prevent ballooning 
 The scaffold should be marketable 
 Reproducible 
 Easily implanted 
 Clinically viable 
 
Above all, safety is the most important objective for the design. If the scaffold is not safe, 
then it is not practical for clinical applications. To ensure that the design is safe, it should be 
made of a biocompatible material. A biocompatible material is one can be implanted in the 
human body, and not be rejected by the organ on which it is implanted. The immune system is 
meant to protect the body from any foreign matter within the body. The material for the scaffold 
must be accepted by the immune system.  
Beyond biocompatibility, the group also needed to consider the composite as a whole, 
specifically the effects that could arise when combining the various components. For the project 
the group will be combining stem cells and a scaffold material. Therefore, it is crucial that the 
union of these materials do not cause any unwanted reactions within the body. Finally, the 
scaffold must be sterile in order to protect patients from sustaining an infection due to 
implantation.  
The next objectives include usefulness and practicality in the design. For this design, the 
scaffold should regenerate cardiac myocytes, provide mechanical stability, and be marketable. 
Based on the initial client statement the scaffold must promote cardiac regeneration. Cell 
viability must also be retained within the scaffold; at minimum the scaffold must foster an 
environment that maintains the initially seeded cells.  
Mechanical stability is another aspect of usefulness that was considered. As previously 
indicated, ventricular aneurisms have a thinning effect on the ventricular wall due to the sub-par 
mechanical properties of the scar tissue. The scaffold design should have mechanical properties 
that resist the forces of the ventricular wall. These properties include: fatigue strength, stiffness, 
and tensile strength.  
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The last measure of usefulness is the scaffold’s marketability. If the scaffold is too 
difficult to implant or manufacture, then its market value reduces. The scaffold should be made 
of a material with appropriate mechanical properties. Also, the scaffold should be reproducible, 
to ensure that market profits can maximized. 
Using the design objectives, a weighted objective tree was made and can be found in 
Figure 3. The two main branches are safety and usefulness, which are weighted similarly. Both 
safety and usefulness are crucial to the successful design of an implantable scaffold. The sub-
branches of safety include the material of the scaffold, its construction, and the sterility. 
Usefulness was sub-categorized by the ability to regenerate cardiac cells, the ability to provide 
mechanical support, and the scaffold’s marketability. The weighted objective tree plays a role in 
elucidating the end goals of the project without extensively limiting the design space. 
 
 
Figure 3: Weighted Objective Tree 
 
 The objectives provide the group with end goals; however, functions are necessary to 
characterize the design. Below is a list of the main functions that the cardiac scaffold must 
perform in order to meet the objectives: 
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Functions: 
 Deliver stem cells 
 Provide an environment for cells to thrive 
 Facilitate surgical simplicity 
 Provide mechanical stability  
 Resist forces induced by heart 
 Resist rubbing forces of the lungs 
 
These functions assist in meeting the stated objectives. Additionally, these functions 
ensure that the final design is able to perform as requested in the design statement. Delivering 
stem cells is a function that must occur to allow the design to regenerate cardiac tissue. Seeding 
the scaffold improperly could result in cell loss or death which would prevent new tissue growth 
and promote design failure. Another point of possible failure with the stem cells is a lack of 
nourishment. It is imperative to successfully seed and deliver stem cells to the infarct region in 
order to ensure viability throughout the regenerative process. 
The scaffold must meet required functions in order to prevent post infarction problems, 
such as aneurysms. The mechanical functions delineated, ensure that once implanted, the 
scaffold is able to prevent aneurysms and provide mechanical stability. As the heart beats, there 
are forces applied to the ventricular wall. Following infarction, there are weakened regions of the 
ventricular wall. The design needs to be able to handle those forces exerted by the ventricular 
wall. Due to the fact that the lungs and heart are so close, especially in a rodent model, the 
scaffold needs to be able to resist rubbing forces from the two organs. Lastly, to ensure that the 
needs of the surgeons are met, a necessary function of the scaffold was to facilitate surgical 
simplicity.    
Since the group does not have unlimited time or funds to complete the research, the scope 
of the project was narrowed. In order to do that, the group compiled a set of constraints to limit 
the design space. The following constraints limit some options for design alternatives, while 
providing attainable goals for the project. 
 
Constraints: 
 Must be implantable 
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 Must be biocompatible  
 Cannot cause harm to the user 
 Must be durable 
 Design costs cannot exceed the $468 budget 
 Must be completed by April 2008  
 
These constraints aid in narrowing the scope of the project, but they do not excessively 
limit potential solutions. The scaffold must be implantable and biocompatible. Following 
implantation the scaffold also needs to be biocompatible. Whenever implanting a material into 
the body, an immune response is elicited. This does not necessarily cause device failure, but it 
must be minimized. For this reason this device needs to be biocompatible, otherwise 
encapsulation may occur and cause device failure. In addition, release of any cytotoxic elements 
from the scaffold post-implantation could render the device unsafe for clinical use. The goal of 
this design is to regenerate lost tissue and heal an infarct site, not to harm the patient. Other 
important constraints that limit the design space are the budget and the time frame. This project 
must be completed within a year’s time, on a budget of $468. These constraints allowed the 
design of the device to be completed within the allotted time and financial boundaries.  
4.3 Specifications 
The following specifications ensure that once implanted, the scaffold will be able to 
withstand the forces of the heart and prevent aneurysms. The scaffold must maintain at least the 
minimum mechanical integrity as defined by previous designs, in order to sustain forces on the 
ventricular wall. The scaffold should have a failure strength that is not statistically different 
before and after cyclic loading of 0.5Hz for 20,000 cycles at 120mmHg. “Design of a Composite 
Scaffold for Myocardial Regeneration Following Infarction” set standards for tensile strength 
and suture retention strength. However fatigue strength must also be tested due to the cyclic 
pressure loading on the ventricular wall. 
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4.4 Revised Client Statement  
 From the delineated objectives, functions, constraints, and specifications, the group was 
able to expand upon the initial client statement to provide a revised client statement, which 
includes all the key points of the project. The revised client statement is shown below: 
Design an implantable scaffold to promote cardiac regeneration for use in the surgical 
treatment of ventricular aneurysms. The scaffold must maintain the minimum required 
mechanical properties as defined by previous designs. It must maintain its fatigue strength under 
conditions of at least 20,000 cycles at 0.5Hz under a pressure of 120mmHg. It must be clinically 
applicable, durable, and biocompatible. It must be safe for use in experimentation, be practical 
for surgical applications, have predictable biomaterial-tissue responses, and require minimal 
maintenance. The scaffold must withstand normal heart pressures, sustain normal heart function, 
facilitate surgical simplicity, and have the ability to self-seal. Finally, the design cannot exceed 
the budget of $468 and it must be completed by April 2008. 
4.5 Design Alternatives 
Based on the delineated objectives, functions, constraints, and specifications, design 
alternatives were formed. Originally two patch materials were selected, UBM and Veritas. A 
brainstorming session with Professor Gaudette, Megan Murphy, Dan Filipe, and the design team 
was held and a morphological chart was created (see Table 2). UBM and Veritas were chosen 
due to preliminary research done by Filipe et al. The suture retention strength and the tensile 
strength were previously characterized for these biomaterials. They were determined by Filipe et 
al. as good biomaterial candidates for cardiac regeneration. In addition, Filipe et al. determined 
that fibrin gel was a good host environment for hMSCs. Therefore, fibrin gel was used as a 
potential means to provide a conducive environment for cell growth. Collagen gel and the 
“microfracture” technique were ideas presented during a brainstorming session. Collagen gel 
seemed promising as a host environment for the cells since it is an abundant ECM protein. The 
“microfracture” technique offered a unique method of nourishing cells with blood flow. hMSCs 
were chosen to promote cardiac regeneration due to the abundance of studies that show their 
capabilities to differentiate into cardiac myocytes. VEGF and MMPs were considered in order to 
enhance cell function and to encourage new tissue formation. Due to budget constraints, VEGF 
and MMPs were not included in any of the design alternatives.  
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Table 2: Morphological Chart 
Function Means 
Maintain similar 
mechanical 
properties to a 
healthy rodent 
heart 
UBM Veritas    
Provide an 
environment 
conducive to cell 
growth 
Fibrin Gel Collagen 
Gel 
“Microfracture” 
in scar tissue 
  
Promote cardiac 
Myocyte 
regeneration 
hMSC’s hMSCs 
and VEGF 
hMSCs and 
MMPs 
hMSCs, 
VEGF, 
and 
MMPs 
 
 
 
 Using this chart and ideas from the brainstorming session a set of five design alternatives were 
recorded.  
 
 Scaffold seeded with hMSCs and punctured 
 Scaffold seeded with hMSCs 
 Two scaffolds with fibrin-seeded gel in between 
 Scaffold with fibrin gel on top sealed with fibrin glue 
 Scaffold injected with hMSCs 
 
The first design involves a scaffold with seeded hMSCs that is implanted onto the heart. 
After implantation blood channels are opened up to provide cell nourishment. The second design 
is a scaffold that is seeded with hMSCs on one side. The scaffold would be prepared for a given 
time prior to implantation to allow cell migration into the patch. The third design uses two 
scaffolds with a fibrin gel solution containing the hMSCs in between. The two scaffolds would 
be sutured together to hold in the gel, then sutured onto the ventricular wall. The fourth design 
uses a scaffold and fibrin gel. In this design, the gel is placed on the scaffold and then fibrin glue 
is used to seal the gel. The scaffold would then be implanted facing down. The fifth design is a 
scaffold that is injected with hMSCs and implanted onto the ventricular wall.  
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Using the objectives, functions, and constraints a set of comparison objectives was 
created to compare the design alternatives. The five designs were then compared using a 
pairwise comparison chart (see Table 3). For each objective, each design was rated from 4 to 1, 
four being the best and one being the worst. After comparing all categories, the numbers for each 
design were tallied up and the design with the most points was chosen as the final design. 
 
Table 3: Pairwise Comparison Chart 
 Design 
Objectives 
Scaffold 
seeded with 
punctures 
Scaffold-fibrin 
gel -scaffold 
Scaffold-fibrin gel 
–fibrin glue 
Scaffold injected 
with fibrin gel 
Safety 4 3 3 1 
Delivery of cells 4 2 2 3 
Promote cell 
viability 
4 3 2 1 
Manufacturability 3 2 4 1 
Surgical simplicity 4 3 2 1 
Cost 4 1 2 3 
Biocompatibility 4 2 1 3 
     
Totals 27 16 16 13 
 
4.6 Final Design 
Based on research, objectives, functions, constraints, specifications, and comparison by 
the pairwise comparison chart, a final design was chosen (see Figure 4). This final design 
incorporates a scaffold seeded with hMSCs followed by syringe needle punctures to the scaffold 
and through the ventricular wall. For this design, no scar tissue is excised from the infarcted 
region. The scaffold is seeded with hMSCs for a given amount of time pre-implantation is 
implanted on top of the scar tissue. This time will be determined via a cell loading assay.  
This design is advantageous due to its simplicity. It is a clinically viable design that will 
be easy to surgically implant, since it only involves one component: the scaffold. Implanting the 
scaffold will require the same surgical technique as the implantation of any acellular patch used 
in the endoventricular patch plasty procedure; however, it also provides regenerative capability 
with the use of hMSCs. In addition, it is one of the safest design alternatives due to its surgical 
ease. Furthermore, the design is cost effective as a result of its simplicity. Finally, the needle 
puncture design allows for sufficient cell delivery and nourishment, to promote differentiation 
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and proliferation of cardiac cells. Overall, this design rated better than the others and was chosen 
to be the final design.   
 
Figure 4: Final Design Schematic 
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Chapter 5: Methodology 
 
In order to evaluate the design alternatives, it was necessary to conduct a series of tests to 
ensure that the scaffold met the specific aims of the project. As a continuation of a previous 
project, “Design of a Composite Scaffold for Myocardial Regeneration Following Infarction,” 
which validated the efficacy of bovine urinary bladder matrix (UBM) and bovine pericardium-
derived collagen matrix (Veritas) for tensile and suture retention strength, it was essential to 
measure the fatigue properties of the two biomaterial considerations: UBM and Veritas. The 
specifications of the biomaterial scaffold are: the scaffold must maintain at least the minimum 
mechanical integrity as defined by previous designs, and the scaffold should have a failure 
strength that is not statistically different before and after cyclic loading of at least 20,000 cycles 
at 0.5Hz under a pressure of 120mmHg. In order to test the fatigue strength, it was necessary to 
design and build a fatigue test apparatus.  
5.1 Fatigue Test Apparatus 
 
 The first step in designing the fatigue apparatus was to set specifications, objectives, 
constraints, and functions. The specification was: it must cyclically infuse and withdraw saline at 
a minimum rate of 0.5Hz at a pressure of 120mmHg for 12 hours. The objectives were: to run 
multiple tests at one time, to provide a uniform pressure which resulted in a ballooning effect on 
the scaffold, to measure both the pressure and the change in height via pressure transducers and a 
sonomicrometer, and to have a continuous system that could run for a 12 hour period. The 
constraints were: it must be sealed to prevent water leakage, it must be able to fasten the 
membranes, it must be able to infuse and withdraw saline at the rate indicated by the 
specifications, and it must maintain a minimum cyclic load of 120mmHg over the 12 hour 
period.  The function was to provide a hydrostatic pressure on the scaffold, forcing it to balloon 
out in a repetitive nature, as a simulation of the forces experienced in vivo to ensure that the 
biomaterial has the necessary fatigue properties for in vivo applications.  
 After delineating the requirements of the system, the group put together several design 
alternatives. One involved a tube used to supply the liquid with the patch fastened to the tip. The 
other design involved a six-well plate with tubes running through the bottom of each well. The 
group considered the objectives, functions, specifications and constraints as they pertained to 
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these two designs. A pairwise comparison chart, shown below in Table 4, was used to determine 
the better design.  
 
 Design 
Objectives 12-well plate Tube 
Prevent water leakage 1 2 
Fasten patch 2 1 
Multiple tests at a time 2 1 
Simulate in vivo forces 2 2 
Continuous system 2 2 
Measures pressure and 
change in height 
2 2 
   
Totals 11 10 
Table 4: Fatigue Apparatus Pairwise Comparison Chart 
 
The results of the pairwise comparison chart indicate that the 12-well plate design is the most 
effective for this design. This design is not only more efficient, but it also provides a better 
method of fastening the scaffold. The only way to properly fasten the scaffold to the tube without 
leakage would be to screw it down; however, since Veritas and UBM is such a delicate material, 
screwing it down is not a feasible option. The final design is pictured below in Figure 5. 
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Figure 5: Schematic of Fatigue Apparatus 
 
Using this schematic, the apparatus was built using the following steps. First, the dimensions of a 
12-well plate were measured on a sheet of acrylic. Then, using a skill saw, the acrylic was cut 
into the proper dimensions. The diameter of each well was measured (about one inch each), and 
four holes of an area given by that diameter were drilled into the acrylic, using a drill press. After 
that, washers were glued with super glue around each hole and well to seal the cover and the well 
plate. Following this, holes were drilled in the bottom of the four chosen wells. Teflon tape was 
placed around the insertion region of the elbow tube connector, and they were inserted into each 
hole with two washers in between the elbow tube connector and the bottom of the well. Next, 
tubing was run from each well to the syringes on the syringe pump. The wells were sealed with 
all-purpose sealant, and the surrounding unused wells were filled with silicone caulking. Finally, 
washers were attached around each well, and a grommet was fastened around the inner ring of 
the washers.  
5.2 Self-Sealing Test 
 
Once the fatigue test apparatus was built, the group was able to run a self-sealing test on the 
two biomaterial considerations: UBM and Veritas. A schematic of the test is shown below in 
Figure 6: 
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Figure 6: Schematic of Self-Seal Experiment 
 
The materials must have the ability to self-seal in order to prevent leakage from suturing and 
from puncturing holes during the in vivo testing. Since minor leakage of the fatigue apparatus 
occurred, a control experiment was performed to ensure that leakage does not affect the results. 
In order to run this test, a given volume of saline was infused into the well of the fatigue 
apparatus until about 120 mmHg of pressure was applied to the scaffold. In the control 
experiment the scaffold was not punctured. For the experiment, a syringe needle was used to 
puncture three holes in the scaffold. If the pressure did not stabilize above 0 mmHg, the scaffold 
was not considered self-sealing. 
5.3 Fatigue Strength Test 
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Following the self-sealing test was the fatigue strength test. Since UBM was unable to 
self seal, only Veritas was considered for fatigue strength. Below is a schematic of the test 
(Figure 7): 
 
Figure 7: Schematic of Fatigue Strength Experiment 
 
The system (syringe, tubing, and well) was filled with saline. Next, any air in the system 
was removed. Then, a pressure transducer line was attached through the tubing. This was used to 
measure the pressure applied to the scaffolds. A sono crystal was sutured to the side of each well. 
Following this, the Veritas scaffold was placed over the well. Then, a washer was used to fasten 
the scaffold tightly over the grommet and washer. Finally, using the four clamps, the well cover 
was tightly held over the well plate so that the four scaffold wells coincided with the holes in the 
cover. This allowed room for the scaffolds to expand. Then, an additional sono crystal was 
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sutured over the scaffold. Finally, the apparatus was submerged to a depth of 12.5 mm under 
water to facilitate signaling between then sono crystals. Plastic wrap was placed over the water 
vessel in order to create a humidified chamber.  
Using LabVIEW 8.0, the syringe pump was programmed to infuse and withdraw the 
saline at 0.5 Hz for 12 hours, while compensating for any pressure drop by infusing additional 
volumes of saline. SonoSoft, the program that records the sono crystal output data, was adjusted 
to the appropriate settings, and measurements of the location of the sono crystals with respect to 
the apparatus were taken. Crystal placement is indicated in the diagram below (Figure 8). 
 
Figure 8: Crystal Placement Diagram 
 
This diagram displays the geometry of the crystals with respect to the apparatus; measurements Z 
and Y were recorded for each test. Then the data was adjusted for this angular discrepancy in 
order to obtain the actual change in height of the scaffold. Finally, the results from the 
transducers were analyzed to ensure that the data reflected a constant expansion height, 
neglecting any initial changes in the height. In addition, the pressure was checked to ensure that 
it remained consistent throughout the procedure. 
5.4 Cell Loading Test 
 
In order to determine whether or not hMSC's migrate into the Veritas scaffold, quantum 
dot loaded hMSC’s were seeded on Veritas. Veritas scaffolds, with dimensions of 2x2 cm, were 
placed in a Petri dish. A 16mm diameter O-ring was placed on top of the Veritas and sealed with 
vacuum grease. The purpose of the O-ring was to hold the media that was concentrated with 
32 
 
20,000 hMSCs. After 7 days, and 14 days, the Veritas was cut into 6 micron cross-sections and 
histologically analyzed using trichrome staining.  
5.5 In Vivo Test 
 
After completing the in vitro testing necessary to validate the efficacy of this design for in 
vivo applications, it was essential to implant the scaffold in the rodent model. WPI IACUC 
approval was obtained in order to purchase nine male Sprague-Dawley, SD, strain (300-350 
grams) rodents from Charles River Laboratory. The rodents were housed at the Gateway Park 
housing facility on the Worcester Polytechnic Institute campus. Due to time constraints, only two 
surgeries were performed. Both surgeries involved implantation of the scaffold in addition to 
three punctures with a 30 gauge needle.  
Two weeks prior to implantation, a 1x1 cm piece of Veritas was seeded with hMSCs at a cell 
density of 2 × 10
5
 cells/cm
2
. This density lies within the average range of cell seeding on 
scaffolds as indicated in Table 1. The Veritas was cut and placed in a 12-well plate. Following 
this, an 8mm diameter washer was placed on top of the Veritas and sealed using vacuum grease. 
The purpose of the washer was to hold 100 microliters of media, which was concentrated at 100 
cells/microliter, on top of the Veritas. The hMSCs were shown to migrate into the Veritas using 
this method with the previously discussed cell loading assay.  
At least three days after the arrival of the rodents, a survival surgery was performed. The 
rodents were anesthetized using IP Ketamine and Xylazine. The chests were shaved, and the 
rodents were intubated for ventilation throughout the procedure. Next, a thoracotomy was 
performed to separate the ribs, using a spring loaded retractor, at the fourth intercostals space. An 
incision of approximately two centimeters in length was made, and a Veritas patch was sutured 
over a portion of the left ventricle. The implants were sutured with a 5-0, 6-0, or 7-0 prolene 
suture. Following implantation, the experiment group received the full thickness punctures with a 
30 gauge syringe needle. Once the bleeding subsided, the chests were closed in layers with a 
combination of 2-0 – 4-0 silk, vicryl and monocryl sutures.  
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Chapter 6: Results 
6.1 Self-Sealing Test 
 The control experiment, which was performed as outlined in the methodology section, 
depicted a minor drop in pressure due to leakage in the fatigue apparatus (Figure 9). The self-
sealing properties of Veritas and UBM were determined based on the procedures outlined in the 
methodology section. The UBM was loaded to a pressure of about 120 mmHg on the fatigue 
apparatus and the scaffold was punctured. Significant leakage occurred immediately after the 
syringe needle was removed and the pressure dropped to nearly 0 mmHg. A picture of the UBM 
post-puncture and a graph of the pressure drop are shown below in Figures 10 and 11. 
 
 
Figure 9: Control Pressure Data 
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Figure 10: UBM Self-Seal Test 
 
 
Figure 11: UBM Self-Seal Pressure Data 
 
The picture illustrates the pooling of saline above the UBM scaffold after it was punctured three 
times. This test determined that UBM does not have self-sealing abilities and therefore is not a 
viable option.   
 The Veritas patch was subjected to the same procedure as the UBM patch to determine if 
it possessed the essential self-sealing property that is required for the scaffold design. After the 
Veritas patch was punctured by the syringe needle, the pressure dropped gradually and 
eventually equilibrated after 300 seconds at 50 mmHg (Figure 12). After this time period, the 
pressure held constant and the leakage ceased. The results of this test determined that the Vertias 
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scaffold showed a self-sealing capability; therefore, additional tests were conducted to determine 
if this material had the necessary characteristics to be incorporated into the design. 
 
Figure 12: Veritas Self-Seal Pressure Data 
6.2 Fatigue Strength Test 
 
 The fatigue strength test was more complicated than initially anticipated. There were 
several factors that dramatically changed the initial design of the fatigue apparatus. The first 
issue was the persistent leakage at various locations. The next factor was the large deformation 
that the Veritas underwent during the cyclic loading. After 24 hours, the deformation that the 
Veritas scaffold underwent caused a significant drop in pressure. This drop in pressure meant 
that the Veritas scaffold was no longer being loaded to a maximum of 120 mmHg. The drop in 
pressure can be seen in the Figures 13-15 below. 
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Figure 13: 24 Hour Cyclic Pressure Loading on Veritas Scaffold 
 
Figure 14: Initial Cyclic Pressure Loading (0-12 minutes) 
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Figure 15: Initial Cyclic Pressure Loading (0-2 minutes) 
 
Since the fatigue strength test was designed to replicate the forces that the Veritas 
scaffold experiences post-implantation, the pressure on the patch must cycle from 5 mm Hg to 
120 mmHg consistently for the duration of the experiment. The first problem was resolved by 
several modifications to the initial design that reduced the leaking to a minimum. The second 
problem required the use of LabVIEW 8.0, which was used to control the syringe pump, as 
previously described, to increase the saline infusion volume when the pressure dropped below 
120 mmHg. This program maintained the necessary pressures that were required for the results 
of the experiment to be considered valid.  
The fatigue test results show that the Veritas deforms slowly initially and undergoes 
minor deformation during the final hours of the experiment. As shown in Figure 16, the initial 
displacement of the Veritas was approximately 1.72 mm. After about 12 minutes, the 
displacement increased to roughly 4.25 mm and remained consistent for nearly three hours. As 
shown in Figure 17, the pressure stayed relatively consistent for the initial 30 minutes. Figures 
18 and 19 are zoomed in displacement and pressure graphs that show the details of the 
waveforms. After 3.6 hours, a minor increase in displacement of 0.25 mm occurred (Figure 20). 
The pressure data for this time period was also consistently at 130 mmHg (Figure 21). At 8 
hours, another increase in displacement of 1.5 mm was observed (Figure 22). This time period’s 
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pressure data increased slightly to 135 mmHg (Figure 23). After 11 hours, the displacement 
actually decreased by 0.4 mm (Figure 24). The pressure data remained the same at 11 hours 
(Figure 25).  
 
Figure 16: Fatigue Test Displacement Data (0-30 min) 
 
 
Figure 17: Fatigue Test Pressure Data (0-30 min) 
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Figure 18: Fatigue Test Displacement Data (0-1 min) 
 
 
Figure 19: Fatigue Test Pressure Data (0-1 min) 
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Figure 20: Fatigue Test Displacement Data (3.6 hr) 
 
Figure 21: Fatigue Test Pressure Data (3.6 hr) 
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Figure 22: Fatigue Test Displacement Data (8 hrs) 
 
Figure 23: Fatigue Test Pressure Data (8 hrs) 
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Figure 24: Fatigue Test Displacement Data (11 hrs) 
 
Figure 25: Fatigue Test Pressure Data (11 hrs) 
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6.3 Cell Loading Test 
 
The cell loading test was essential for determining the time period that was required to allow 
the hMSCs to migrate into the Veritas scaffold prior to implantation. About 20,000 hMSC’s were 
seeded on a 2cm x 2cm section of Veritas. Figure 26 is a control trichrome stain of unseeded 
Veritas.  
    
 
Figure 26: Trichrome Control of Unseeded Veritas 
 
After 24 hours, no cell migration occurred. Figure 27 is an image of a trichrome stain on Veritas 
that was seeded for 7 days. The cell furthest from the top seeded portion of the Veritas migrated 
800 μm into the scaffold. 
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Figure 27: Trichrome Seeded for 7 Days 
 
Figure 28 is an image of a trichrome stain on Veritas that was seeded for 14 days. The cell 
furthest from the top seeded portion of the Veritas migrated 1200 μm. 
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Figure 28: Trichrome Seeded for 14 Days 
     
The purpose of this experiment was to find the ideal duration of seeding time prior to 
implantation, which would enable larger densities of hMSCs to be seeded onto the scaffold. 
Below is a graph (Figure 29) that analyzes migration distance over time. From this graph it can 
be determined that the optimal seeding time is from 10 to 16 days.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Results of Cell Loading Test 
 
6.4 In Vivo Results 
 
Two groups, each consisting of eight scaffolds, were seeded about three weeks prior to 
implantation. From each group, four scaffolds were taken for histological analysis. Two 
scaffolds were taken at 10 days, and two were taken at 16 days. Each was histologically analyzed 
using trichrome staining. Figure 30 is an image of the group 1 Veritas after 10 days. Figure 31 is 
an image of the group 1 Veritas after 16 days. 
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Figure 30: Group 1 Veritas at 10 Days 
 
 
Figure 31: Group 1 Veritas at 16 Days 
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The furthest cell in the 10 day group 1 image migrated about 1200µm.  The furthest cell in the 16 
day group 1 image migrated about 2800 μm. The analysis of these scaffolds was used to ensure 
that the implanted scaffolds were optimally seeded.  
 After about three weeks of scaffold culturing time, two scaffolds were implanted in 
rodents. Due to time constraints, only two surgeries were performed; however, both were 
successful in implanting the design. The first rodent weighed about 300g. About 30 minutes 
before the procedure, it was administered 0.7mL Ketamine and 0.1mL Xylazine. Minutes prior 
to the implantation of the scaffold, the rodent died due to a technical error in the ventilation 
system. The scaffold was still successfully implanted since the rodent died from errors unrelated 
to the design. The second rodent weighed about 350g. Thirty minutes prior to surgery, the rodent 
was administered 0.85mL Ketamine and 0.1mL Xylazine. During the procedure, the rodent died 
due to small incision in the lung. This procedure resulted in successful implantation of the 
scaffold, and the death of the rodent was unrelated to the design.  
 
Figure 32: Application of the Final Design in the Rodent Heart 
 
Figure 32 shows the successful application of the design in the rodent heart during the procedure. 
As a result of two successful implantations of the design, it was determined that this design is 
surgically simple and clinically applicable.   
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Chapter 7: Analysis and Discussion 
 The purpose of much of the in vitro testing was not only to qualify the efficacy of the 
design, but also to determine the benefits of certain design components. The first test, the self-
sealing test, was used not only to determine the efficacy of the two biomaterials, but also to 
determine the better scaffold choice for this design. The results of the self-seal test indicated that 
UBM did not have the ability to self-seal; however, Veritas did have this ability. Therefore, the 
test not only removed UBM from the biomaterial scaffold considerations, but it also advanced 
Veritas onto further testing.  
 As shown in Figure 10, the graph of the UBM pressure decreases post-needle puncture. 
This detail along with the pooling of saline above the scaffold in the apparatus indicated that 
UBM did not have self-sealing potential. One note that must be addressed about this graph is the 
slight peak about half way through the decrease in pressure. This was a result of an accidental 
disturbance of the apparatus during the pressure recording time. Since human error was a result 
of this discrepancy, it can be disregarded. 
 The self-seal test for Veritas was more successful than that of the UBM. The pressure 
was shown to stabilize after 300 seconds at 60 mmHg. While this data proves that Veritas self-
seals, it was expected that the Veritas would self-seal at a faster rate; however, the leaky 
apparatus may have attributed to the decrease in pressure. Nonetheless, Veritas displayed the 
necessary self sealing ability as stated by the specifications.   
 Following the self-seal test, Veritas was tested for its fatigue strength, which was an 
additional design criterion previously specified. The initial testing of Veritas resulted in failure; 
however, these results were mostly due to a failure in the apparatus. Leakage occurred over the 
course of the 24 hour period, resulting in a decrease in the infusion volume, which therefore 
decreased the pressure applied on the scaffold. Figures 11-13 illustrate this response. One note 
on the graphs is needed to explain the rough cycle waveform. This was not only due to down-
sampling of the data, which was done in order to graph the information, but it was also due to a 
skip that occurred consistently in the cycles due to the syringe pump. 
Due to consistent pressure drops during the fatigue testing, LabVIEW programming was 
required to apply a consistent pressure thereby varying the infusion volume. As a result, the data 
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in Figures 16-25 was acquired. More deformation occurred than was expected; however, overall 
(not including the initial deformation) the displacement only increased by about 2 mm 
throughout the 12 hour period. The pressure data did not vary by more than 10 mmHg. The 
variation was due to the delay between the acquisition of the pressure data and the reaction of the 
LabVIEW program. Further testing is necessary for more conclusive data on the fatigue strength 
of Veritas.  
The results of the migration test were crucial in determining the cell-seeding time prior to 
implantation. The migration tests not only ensured that hMSCs have the ability to migrate 
through the scaffold, implying that they can also migrate out, but the test also showed that 
increased cell densities can be seeded on the scaffold. If an increase in cell density was desired, 
then initial cell seedings could allow cells to migrate into the scaffold for a given amount of time 
followed by subsequent surface seedings. This would improve chances of myocardial 
regeneration by increased cell saturation, cell viability, increased proliferative potential of 
cardiac myocytes, and/or increased differentiation of the stem cells. In addition, the histology 
figures of the cell loading assay were acquired while the method of cell seeding on the Veritas 
was still being perfected. As a result, it can be assumed that subsequent seedings of hMSCs on 
Veritas will result in an increase in the abundance of cells and potentially further cell migration.  
Finally, the results of the in vivo testing proved the surgical simplicity and clinical 
applicability of the design. Due to technical errors, both rodents perished during the surgery; 
however, a novice surgeon was still able to implant the scaffold. Therefore, since the deaths were 
unrelated to the implantation method, it was concluded that the design was successfully 
implanted.  
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Chapter 8: Conclusions 
 
Based on in vitro and in vivo tests that were completed, it can be concluded that this 
design is a clinically applicable device for use in the surgical treatment of ventricular aneurysms. 
As mentioned, Filipe et al.
8
 proved that both UBM and Veritas scaffold materials contain the 
necessary mechanical properties for cardiac applications. These include tensile strength, strain, 
and suturability. The design presented in this project concludes that Veritas meets all additional 
specifications as defined by the parameters to be a used as a clinically applicable scaffold for 
cardiac regeneration. 
The UBM scaffold material was unable to self seal after five minutes following three 
syringe punctures. Due to this failed test it was concluded that UBM would not be an appropriate 
scaffold material for this application. The Veritas did sufficiently seal following the five minute 
self-seal test. From these results, it was concluded that Veritas would be the chosen material for 
the final design. 
The next test completed was the fatigue test. The Veritas fatigue test was run three 
independent times. Results from this test indicate that Veritas reached a maximum deformation 
of approximately 5.7mm. This was acceptable for the given specifications. These results indicate 
that Veritas will be able to withstand the forces of the heart over a long term period, ensuring 
that the design presented in this project is clinically applicable.      
The cell loading test was done to ensure that the cells could be successfully loaded onto 
the scaffold material. Following the seeding of the cells and the 16 day intubation period, it was 
found that the cells migrated a maximum distance of 2800μm into the scaffold material. It can be 
concluded that Veritas provides a sufficient cell loading ability. This ability can lead to a proper 
delivery method of cells into the heart following infarction. 
The final test of the efficacy of the design was the in vivo implantation. The scaffolds 
were implanted onto the ventricular wall of male Sprague-Dawley rats and the scaffold material 
was punctured. The scaffolds were successfully implanted by a novice surgeon. Based on the 
results of this test, it was concluded that the design facilitates surgical simplicity.  
Following all in vitro and in vivo tests it can be concluded that the design is a novel 
method of safely delivering hMSCs to the heart. Based on the functions, specifications, 
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constraints, and objectives the design has accomplished what was desired. It has the necessary 
mechanical properties to be effective as well as the porosity needed to self seal and load cells.  
Overall, it can be concluded that the problem given in the initial client statement was 
solved. A clinically applicable scaffold, which may aid in cardiac regeneration, was successfully 
designed and implanted. However, further in vivo testing must be done to determine if the final 
design induces cardiac regeneration.  
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Chapter 9: Future Recommendations 
 
There are many aspects of this project that were not pursued due to time and financial 
constraints. The $468 budget and the eight month deadline were limiting factors in the amount of 
research that could be completed. This section details suggestions for future research. 
 The fatigue apparatus was vital for characterization of a scaffold for use in cardiac 
regeneration. Many problems were encountered during the manufacturing process that 
diminished the accuracy of the obtained data. Future implementations of the fatigue apparatus 
should include a non-modular construction, a higher quality syringe pump, a unified data 
collection system, and a less intricate tubing system. Significant leakage occurred during 
experimentation due to the modular construction of the apparatus and the complex tubing 
system. Mechanical complications with the syringe pump caused minute discrepancies in the 
pressure and height waveforms. The use of two computer systems for data collection during the 
fatigue test increased the probability of inaccuracy, increased the size of the fatigue apparatus 
package, and required complex manipulation of the data for analysis. Execution of these 
recommendations may provide more accurate results.    
 The chosen design uses saline filled syringes that are injected through the scaffold and 
the ventricular wall. The saline solution can be augmented with possible additives that may assist 
in new tissue growth. These additives were omitted due to budget constraints. The first additive 
that could be considered is vascular endothelial growth factor (VEGF). VEGF is a naturally 
occurring growth factor that induces angiogenesis and increases endothelial permeability
45
. 
Studies have shown that VEGF enhances endothelialization, which is vital for cell survival and 
proliferation.
43
 Matrix metallo-proteinases (MMPs) are an additional additive that could be 
incorporated into the design. MMPs are enzymes that control ECM remodeling following 
infarction.
44
 The use of MMPs may encourage new tissue formation through the degradation of 
scar tissue. Therefore it is recommended that using paracrine factors may improve new tissue 
formation over stem cells alone. 
 The surgery that was performed for this project required more time and funding that was 
allotted. As a result, future studies should incorporate a larger sample size and a longer 
implantation period. Due to budget constraints, only eight rats were purchased. Increasing the 
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sample size will allow a more accurate statistical analysis. Due to time constraints, there was no 
implantation period. Extending the implantation period may provide more developed results.  
 The ultimate goal of this research is to provide an implantable scaffold that assists in the 
treatment of ventricular aneurysms and myocardial infarction. The financial and time constraints 
limited the incorporation of the components presented in this section. The recommendations 
presented here may lead to more constructive findings.  
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Appendix B: Sonomicrometry User Manual 
 
60 
 
 
 
 
 
61 
 
62 
 
 
 
 
 
63 
 
 
 
 
 
64 
 
 
 
 
 
 
